

INTROGEN THERAPEUTICS INC
Form SC 13G
February 13, 2002

Schedule 13G

Page 1 of 4

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO.)*

Introgen Therapeutics, Inc.

(Name of Issuer)

Common Stock, \$0.001 par value

(Title of Class of Securities)

46119F 10 7

(CUSIP Number)

December 31, 2001

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

Schedule 13G

Page 2 of 4

CUSIP No. 46119F 10 7

1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only).

David G. Nance

2. Check the Appropriate Box if a Member of a Group (See Instructions)
(a)
(b)

Edgar Filing: INTROGEN THERAPEUTICS INC - Form SC 13G

3. SEC Use Only

4. Citizenship or Place of Organization United States citizen

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5. Sole Voting Power 2,540,698

6. Shared Voting Power 0

7. Sole Dispositive Power 2,540,698

8. Shared Dispositive Power 0

9. Aggregate Amount Beneficially Owned by Each Reporting Person 2,540,698

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

11. Percent of Class Represented by Amount in Row (9) 11.8%

12. Type of Reporting Person (See Instructions)

IN

Schedule 13G

Page 3 of 4

ITEM 1.

(a) Introgen Therapeutics, Inc., a Delaware corporation

(b) 301 Congress Ave., Suite 1850, Austin, TX 78701

ITEM 2.

(a) David G. Nance

(b) 301 Congress Ave., Suite 1850, Austin, TX 78701

(c) USA

(d) Common Stock, par value \$0.001 per share

(e) 46119F 10 7

ITEM 3. NOT APPLICABLE

ITEM 4. OWNERSHIP

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

Edgar Filing: INTROGEN THERAPEUTICS INC - Form SC 13G

- (a) Amount beneficially owed: 2,540,698
- (b) Percent of class: 11.8%
- (c) Number of shares as to which the person has:
 - (i) Sole power to vote or to direct the vote 2,540,698
 - (ii) Shared power to vote or to direct the vote 0
 - (iii) Sole power to dispose or to direct the disposition of 2,540,698
 - (iv) Shared power to dispose or to direct the disposition of 0

ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

NOT APPLICABLE

ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

Reporting Person has the right to receive and the power to direct the receipt of dividends from or the proceeds from the sale of 2,215,605 shares by virtue of his position as the Chief Executive Officer and sole stockholder of each of Developtech Resources Corporation, Debouchement, Ltd. and Domecq Technologies, Inc.

ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY

NOT APPLICABLE

ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP

NOT APPLICABLE

ITEM 9. NOTICE OF DISSOLUTION OF GROUP

NOT APPLICABLE

Schedule 13G

Page 4 of 4

ITEM 10. CERTIFICATION

- (a) Not applicable.
- (b) Not applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Edgar Filing: INTROGEN THERAPEUTICS INC - Form SC 13G

February 12, 2002

Date

/s/ DAVID G. NANCE

Signature

DAVID G. NANCE

Name/Title

ATTENTION: INTENTIONAL MISSTATEMENTS OR OMISSIONS OF FACT CONSTITUTE FEDERAL
CRIMINAL VIOLATIONS (SEE 18 U.S.C. 1001)